Cemil Bilir

Akademik Profiller

1. 1
   Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancerBMC Cancer
   2024
2. 2
   Correction: Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (BMC Cancer, (2024), 24, 1, (16), 10.1186/s12885-023-11783-5)BMC Cancer
   2024
3. 3
   Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRCJournal of Oncology Pharmacy Practice
   2024
4. 4
   Determinants of Cancer-Related Online Information-Seeking Intentions of Cancer Patients Receiving ChemotherapyOnline Türk Sağlık Bilimleri Dergisi
   2023
5. 5
   Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatmentEuropean Review for Medical and Pharmacological Sciences
   2023
6. 6
   Effect of the MiR-99b and MiR-135b on peritoneal carcinomatosis and liver metastasis in colorectal cancerClinics
   2023
7. 7
   Prospective analysis of febrile neutropenia patients with bacteraemia: the results of an international ID–IRI studyInternational Journal of Antimicrobial Agents
   2023
8. 8
   The cytotoxic effects of indoleamine 2, 3-dioxygenase inhibitors on triple negative breast cancer cells upon tumor necrosis factor α stimulationJournal of Cancer Research and Therapeutics
   2023
9. 9
   The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapyClinical and Translational Oncology
   2023
10. 10
    By 2022, Cancer is Now a More Chronic Disease with Chronic Difficulties to Go Along with ItJournal of Oncological Science
    2022

Yayın listesi ORCID kaydından alındı.